News
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...
Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...
21h
Stockhead on MSNBig pharma takes notice as Novo Nordisk puts Clever Culture’s APAS to the testClever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
Buying stocks that are trading at cheap valuations can set you up for some big gains later on. And it can minimize the risk ...
NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 Best Semiconductor Stocks to Buy According to Reddit. NVIDIA Corporation ...
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results